Zacks Research Upgrades Privia Health Group (NASDAQ:PRVA) to “Hold”

by · The Markets Daily

Privia Health Group (NASDAQ:PRVA – Get Free Report) was upgraded by investment analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a note issued to investors on Wednesday,Zacks.com reports.

Other equities analysts also recently issued reports about the company. Barclays lowered their price target on Privia Health Group from $25.00 to $24.00 and set an “equal weight” rating for the company in a report on Tuesday, May 26th. Canaccord Genuity Group cut their price objective on shares of Privia Health Group from $35.00 to $34.00 and set a “buy” rating on the stock in a report on Friday, May 8th. Citigroup restated a “buy” rating on shares of Privia Health Group in a research report on Thursday, July 23rd. Evercore set a $26.00 target price on shares of Privia Health Group in a research report on Wednesday, April 8th. Finally, Weiss Ratings raised shares of Privia Health Group from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, July 2nd. Eleven equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Privia Health Group presently has an average rating of “Moderate Buy” and an average target price of $31.15.

Get Our Latest Stock Analysis on Privia Health Group

Privia Health Group Stock Performance

PRVA opened at $22.00 on Wednesday. Privia Health Group has a one year low of $19.08 and a one year high of $28.82. The company has a market cap of $2.77 billion, a P/E ratio of 137.51, a PEG ratio of 1.90 and a beta of 0.85. The business’s 50-day simple moving average is $24.61 and its 200-day simple moving average is $23.35.

Insiders Place Their Bets

In other news, CFO David Mountcastle sold 24,734 shares of the stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $27.50, for a total value of $680,185.00. Following the completion of the sale, the chief financial officer directly owned 186,728 shares of the company’s stock, valued at approximately $5,135,020. This represents a 11.70% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Parth Mehrotra sold 105,439 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $22.55, for a total transaction of $2,377,649.45. Following the transaction, the chief executive officer owned 450,004 shares in the company, valued at approximately $10,147,590.20. This trade represents a 18.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 452,357 shares of company stock valued at $11,436,655 over the last quarter. Company insiders own 5.70% of the company’s stock.

Institutional Trading of Privia Health Group

Several institutional investors and hedge funds have recently bought and sold shares of PRVA. GAMMA Investing LLC increased its position in Privia Health Group by 14.0% in the 2nd quarter. GAMMA Investing LLC now owns 4,819 shares of the company’s stock valued at $124,000 after acquiring an additional 592 shares during the period. State of Alaska Department of Revenue raised its stake in Privia Health Group by 1.3% during the 4th quarter. State of Alaska Department of Revenue now owns 65,747 shares of the company’s stock valued at $1,558,000 after acquiring an additional 823 shares during the last quarter. PNC Financial Services Group Inc. raised its stake in Privia Health Group by 8.8% during the 1st quarter. PNC Financial Services Group Inc. now owns 10,361 shares of the company’s stock valued at $213,000 after acquiring an additional 840 shares during the last quarter. ProShare Advisors LLC lifted its position in Privia Health Group by 4.1% during the 4th quarter. ProShare Advisors LLC now owns 22,576 shares of the company’s stock worth $535,000 after acquiring an additional 898 shares during the period. Finally, Vanguard Personalized Indexing Management LLC lifted its position in Privia Health Group by 5.9% during the 4th quarter. Vanguard Personalized Indexing Management LLC now owns 16,250 shares of the company’s stock worth $385,000 after acquiring an additional 903 shares during the period. Hedge funds and other institutional investors own 94.48% of the company’s stock.

Key Headlines Impacting Privia Health Group

Here are the key news stories impacting Privia Health Group this week:

  • Positive Sentiment: Raised 2026 outlook: Management increased full-year guidance for attributed lives to 1.625–1.650 million, practice collections to the high end of $3.65–$3.75 billion, GAAP revenue to the high end of $2.35–$2.45 billion, and adjusted EBITDA to $145–$155 million. It also expects approximately 70%–80% of adjusted EBITDA to convert to free cash flow. Privia Health Reports Strong Second Quarter and Year-to-Date 2026 Results
  • Positive Sentiment: Strong quarterly growth: Q2 revenue rose 21.4% year over year to $632.6 million, exceeding the $597.3 million consensus. Adjusted EPS was $0.19 versus the $0.07 analyst estimate, while net income increased to $9.0 million from $2.7 million. Privia Health Q2 Earnings Report
  • Positive Sentiment: Operating momentum improved: Implemented providers grew 10.1% to 5,644, value-based-care attributed lives increased 19.2% to 1.647 million, and adjusted EBITDA climbed 29.1% to $37.4 million. Adjusted EBITDA margin expanded to 28.3% from 25.2%.
  • Neutral Sentiment: Analyst comparisons are complicated by differing definitions: GAAP diluted EPS was $0.07, while adjusted EPS was $0.19. The adjusted figure benefited from add-backs, including $19.4 million of non-cash stock compensation expense.
  • Negative Sentiment: Cash-flow concerns: Privia used $48.4 million in operating cash during the first half, largely because accounts receivable increased by $172.4 million. Cash declined to $412.2 million from $479.7 million at year-end.
  • Negative Sentiment: PRVA’s valuation remains demanding, with a reported price-to-earnings ratio near 150. Heavy insider selling cited in recent data may also weigh on sentiment, even though the company’s operating results and outlook improved.

Privia Health Group Company Profile

(Get Free Report)

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.

See Also